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The importance of pre- and postnatal develop-
ment for the onset of diseases later in life is rec-
ognized but not well understood. Thus,
assessing fetal and infant exposure to environ-
mental neurotoxicants and the developmental
implications may provide important insights
into the pathogenesis of neurodegenerative dis-
eases. Studies in mice have identiﬁed a window
of critical vulnerability in neonatal brain
development during which persistent neuro-
toxic effects may be induced by a diverse array
of xenobiotics, ranging from pharmacologic
substances (e.g., ketamine; Fredriksson et al.
2004) to environmental organohalogens [e.g.,
1,1-bis(4-chlorophenyl)-2,2,2-trichloroethane
(DDT), polychlorinated biphenyls (PCBs),
and polybrominated diphenyl ethers (PBDEs);
Eriksson 1997; Eriksson et al. 2001; Eriksson
and Talts 2000; Viberg et al. 2002, 2003a,
2003b]. This critical developmental phase
coincides with the period of brain growth
spurt (BGS), which is characterized by a num-
ber of neurodevelopmental changes, including
dendritic and axonal outgrowth, establishment
of neural connections, and synaptogenesis
(Davison and Dobbings 1968). For the
PBDEs, different neurotransmitter systems
have been suggested as potential targets for the
neurotoxic effects (Mariussen and Fonnum
2003; Meerts et al. 2004; Viberg et al. 2002,
2003a, 2004b), even if the mechanisms by
which these systems are damaged during the
BGS are unclear.
Human exposure to PBDEs is of growing
concern worldwide. For example, PBDE levels
have increased signiﬁcantly in the breast milk
of Swedish women over the past three decades
(Noren and Meironyte 2000). The trend in
the United States is the same (Schecter et al.
2005) but with levels of PBDEs in blood and
adipose tissue lipid that are 10–100 times
those in human tissues in Europe (Schecter
et al. 2003). The reason for this difference is
not clear. One of the most common PBDE
congeners found in human and environmental
samples (Darnerud et al. 2001) is PBDE-99,
which has been shown to impair spontaneous
behavior and habituation capability in adult
mice after neonatal exposure to relatively mod-
erate doses (Viberg et al. 2002). In addition
the effects appear to worsen with increasing
age (Viberg et al. 2004a). It remains to be
deﬁned how such late responses to early expo-
sure may reﬂect the long-term consequences of
brain development being disrupted during sen-
sitive stages. Here we present a proteomics
approach toward understanding the primary
damaging events that occur in the developing
brain during PBDE-99 exposure and toward
ﬁnding potential biomarkers of developmental
neurotoxicity for this group of compounds.
We report protein level changes in the striatum
and in the hippocampus, both of which are
part of the developing cholinergic and cate-
cholaminergic systems that have been impli-
cated as targets for some PBDEs (Mariussen
and Fonnum 2003; Meerts et al. 2004; Viberg
et al. 2002, 2003a, 2004b). This ﬁnding sug-
gests neurodegeneration and aberrant neuro-
plasticity as possible causes of injury.
Materials and Methods
Animals. We purchased pregnant NMRI mice
from B&K (Sollentuna, Sweden). Mice were
individually housed in plastic cages at 22°C
ambient temperature with a 12/12-hr
light/dark cycle, and supplied ad libitum
with standardized pellet food (Lactamin,
Stockholm, Sweden) and tap water. Cages
were inspected for newborn pups twice a day
(0800 and 1800 hr), and found pups were
assigned day 0. Litter size was adjusted to
10–12 pups within 24 hr of birth by random
culling. Litters containing pups of both sexes
were housed with their mothers up to an age
of 4 weeks. The animals were treated
humanely and with regard for alleviation of
suffering; animal experiments were conducted
in accordance with and after approval from
the local ethical committee (Uppsala
University and Agricultural Research Council)
and by the Swedish Animal Welfare Agency
(license 2003/87).
Treatments and sample collection. The
polybrominated diphenyl ether PBDE-99
(2,2´,4,4´,5-pentabromodiphenyl ether),
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Exposure to the brominated ﬂame retardant 2,2´,4,4´,5-pentabromodiphenyl ether (PBDE-99) during
the brain growth spurt disrupts normal brain development in mice and results in disturbed sponta-
neous behavior in adulthood. The neurodevelopmental toxicity of PBDE-99 has been reported to
affect the cholinergic and catecholaminergic systems. In this study we use a proteomics approach to
study the early effect of PBDE-99 in two distinct regions of the neonatal mouse brain, the striatum
and the hippocampus. A single oral dose of PBDE-99 (12 mg/kg body weight) or vehicle was admin-
istered to male NMRI mice on neonatal day 10, and the striatum and the hippocampus were isolated.
Using two-dimensional ﬂuorescence difference gel electrophoresis (2D-DIGE), we found 40 and
56 protein spots with signiﬁcantly (p < 0.01) altered levels in the striatum and the hippocampus,
respectively. We used matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry
(MALDI–ToF–MS) to determine the protein identity of 11 spots from the striatum and 10 from the
hippocampus. We found that the levels of proteins involved in neurodegeneration and neuroplasticity
(e.g., Gap-43/neuromodulin, stathmin) were typically altered in the striatum, and proteins involved in
metabolism and energy production [e.g., α-enolase; γ-enolase; ATP synthase, H+ transporting, mito-
chondrial F1 complex, β subunit (Atp5b); and α-synuclein] were typically altered in the hippocampus.
Interestingly, many of the identiﬁed proteins have been linked to protein kinase C signaling. In con-
clusion, we identify responses to early exposure to PBDE-99 that could contribute to persistent
neurotoxic effects. This study also shows the usefulness of proteomics to identify potential biomarkers
of developmental neurotoxicity of organohalogen compounds. Key words: 2D-GE, brain development,
brain growth spurt, MALDI–ToF–MS, neonatal, neurodegeneration, PBDE-99, PKC, proteomics.
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[Online 6 October 2005]University, Stockholm, Sweden), was dis-
solved in a 1:10 mixture of egg lecithin
(Merck, Darmstadt, Germany) and peanut oil
(Oleum arachidis), and sonicated with water to
obtain a 20% (w/w) water:fat emulsion con-
taining 1.2 mg/mL PBDE-99. On postnatal
day 10, mice (three to four litters) were given
10 mL/kg body weight (bw) of this emulsion
as a single oral dose (12 mg/kg bw PBDE-99)
via a metal gastric tube; control mice (three to
four litters) received vehicle only. Animals
were sacrificed by cervical dislocation 24 hr
after treatment. The brains were rapidly dis-
sected out, and the hippocampus and the
striatum from each brain were isolated, rapidly
put on ice, and stored at –70°C until further
processing. The entire procedure from sacri-
ﬁce to when each brain region was put on ice
was completed within 3 min for each mouse.
Sample preparation. We separately
pooled (to reduce variance from individual
variation) control and treated samples from
the striatum (~ 160–180 mg wet weight each)
and the hippocampus (~ 250–270 mg wet
weight each), as illustrated in Figure 1. Frozen
tissue from three pups in each pool was
lysed with 4 volumes of 9.6 M urea, 4%
3-[(3-cholamidopropyl)dimethyl-
ammonio]-1-propanesulfonate (CHAPS),
70 mM dithiothreitol (DTT); 5% immo-
bilized pH gradient (IPG) buffer, pH 3–10,
and homogenized with a sonicator (Branson
Sonifier cell disruptor B15; Kebo-Grave,
Stockholm, Sweden) in an Eppendorf tube on
ice in pulses of 10 sec, followed by ultra-
centrifugation for 1 hr at 100,000 × g (Ultra
centrikon; Kontron, Neufarn, Germany). We
collected and cleaned supernatants from lipids
and nucleic acids using the 2D Clean-up Kit
(GE Healthcare, Uppsala, Sweden) according
to the manufacturer’s instructions. The total
protein concentration of each sample was
determined using the 2D Quant Kit (GE
Healthcare) according to the manufacturer’s
protocol. To minimize protease activity, we
performed the entire procedure on ice when-
ever possible. 
2D-DIGE. For two-dimensional fluo-
rescence difference gel electrophoresis
(2D-DIGE), we labeled 50 µg each of control,
treated, and internal standard protein sample
with cyanine dye (Cy)3, Cy5 and Cy2, respec-
tively, according to the manufacturer’s descrip-
tions for CyDye DIGE Fluor minimal dyes
(GE Healthcare). The internal standard was a
mixture of equal amounts of protein from all
pools (Figure 1). Four 2D-DIGE gels each for
the striatum and the hippocampus (i.e., a total
of eight gels) were run in parallel. Two of the
gels (gels 4 and 8; Figure 1) were technical
replicates with 150 µg unlabeled protein from
a pool of control animals added to allow for
protein identiﬁcation (see below) directly from
a 2D-DIGE gel. Before the first-dimension
isoelectric focusing (IEF), a 50-µg aliquot from
each of the three labeling mixes (see above) was
combined with rehydration buffer [containing
7 M urea, 4% (w/v) CHAPS, 1% (w/v) DTT,
and 0.5% (v/v) Pharmalytes (GE Healthcare)
that covered the pH interval (pH 4–7) of the
IPG strips], to give a ﬁnal volume of 450 µL.
In-gel rehydration of the 24-cm IPG strips
(GE Healthcare) with the 450-µL rehydration
buffer (including the protein sample), was
performed at room temperature in the dark
for 12 hr according to the manufacturer’s
instructions (GE Healthcare). IEF was run on
an IPGPhor (GE Healthcare) at 500 V for
1 hr, at 1 kV for 1 hr, and at 8 kV until a
total of 64 kVh was reached. After IEF, the
strips were equilibrated for 2 × 15 min by
gentle shaking in a buffer containing 50 mM
Tris–HCl (pH 6.8), 6 M urea, and 2%
sodium dodecyl sulfate (SDS), supplemented
with 2% DTT in the first equilibration step
and 2.5% iodoacetamide in the second. For
the second dimension SDS–polyacrylamide
gel electrophoresis (SDS–PAGE), the equili-
brated strips were put on top of precast large-
format 12.5% polyacrylamide gels (GE
Healthcare) and were run using an Ettan
DALTsix large-format vertical system (GE
Healthcare). The gels were run at 5 W for
45 min before increasing to 11 W per gel
until the bromophenol blue dye front had
reached the bottom of the gel. The tempera-
ture was kept constant at 27°C. The gels were
scanned with a Typhoon 9400 fluorescence
scanner (GE Healthcare).
Image analysis and statistics. The ﬂuores-
cent images of the 2D-DIGE gels were ana-
lyzed using the DeCyder software suite (GE
Healthcare) with default settings. The Cy2,
Cy3 and Cy5 images for each gel were merged
in the Differential In-gel Analysis DeCyder
module, and spot boundaries were automati-
cally detected. Spots containing dust particles
and other nonproteinaceous artifacts were
flagged manually and excluded from further
analysis. We matched spots from the different
gels using the automatic matching function in
the Biological Variance Analysis DeCyder
module after prior landmark settings and con-
firmed manually by comparing each spot
against the master gel. The normalized vol-
umes for Cy3 and Cy5 were exported from the
DyCyder software and analyzed in the R com-
puting environment from the GNU Project
web server (http://www.r-project.org/) using
the limma package (Bioconductor Software
Project, Cambridge, MA, USA; http://www.
bioconductor.org; Smyth and Speed 2003).
Normalized volume refers to the volume nor-
malized across the three dyes and across the gels. 
To determine differential expression of
proteins, we used the moderated t-statistics as
used, as previously implemented by Smyth
(Smyth and Speed 2003). For the statistical
analysis, we used the log2 of the normalized
volumes. We used only proteins present (local-
ized) across all four gels, thereby allowing for
no missing values. For each gel and spot, the
ratio Cy5/Cy3 was calculated, and ratios less
than unity were folded over by inverting the
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Figure 1. Experimental design and pooling procedure. Individual control (1–9) and treated (10–18) tissue
samples were separately pooled into three control (1–3) and treated (5–7) pools per sample type (striatum
and hippocampus). In addition to these biological replicates, we made a technical replicate of pools 1 and
5 (4 and 8, respectively). Control pools (1–4) were labeled with Cy3, treated pools (5–8) with Cy5, and a mix-
ture of all pools (pools 1–8) with Cy2 as internal standard. Four gels were run in parallel, as indicated, with
extra unlabeled protein added to gel 4.ratio value. The upper 95th percentile of these
ratios was taken as a practical measure of a
ratio above which real effects could be expected
(Tonge et al. 2001). We then calculated the
log2 95% ratios for each gel. To predict a value
above which the absolute spot ratio for a future
gel is likely to signify a real effect and not be
caused merely by chance, we calculated one
limit for the striatum and another one for the
hippocampus as follows:
log (prediction limit) = mean + t3
95% × SD × √
——–
(1+1/4)
–
.
The t3
95% is the upper 95% point of the stu-
dent’s t-distribution with 3 degrees of freedom
because four gels were used to estimate the SD
of the log 95% ratios, and the mean is the
average of the 95% ratios (Tonge et al. 2001).
Protein identification. After the image
analysis, gels containing the additional load of
proteins unlabeled proteins (gel 4; Figure 1)
were stained with Colloidal Coomassie Brilliant
Blue G (Acros Organics, Geel, Belgium) and
matched to the ﬂuorescent 2D-DIGE images.
We picked selected spots (see “Results”) using a
spot-picking instrument made in-house and
stored the gel plugs (with a diameter of 2 mm)
in Eppendorf tubes at –70°C until analysis. We
also picked some spots from a preparative gel
with a protein load of 400 µg that covered the
same pH range as the 2D-DIGE gels and run
similarly. For peptide mass ﬁngerprinting, pro-
teins were digested with trypsin according to
Havlis et al. (2003). Briefly, gel plugs were
washed twice in 100 µL 50 mM ammonium
bicarbonate/50% methanol for 30 min fol-
lowed by an additional wash in 75% acetoni-
trile (ACN) for 10 min. Plugs were dried
followed by in-gel digestion using 10 µL
(200 ng) trypsin in 20 mM ammonium
bicarbonate for 60 min at 37°C. Peptides were
extracted with 50% ACN/0.1% triﬂuoroacetic
acid (TFA, completely dried, and resuspended
in 50% ACN/0.1% TFA. Before adding the
peptide samples to plates for matrix-assisted
laser desorption ionization time-of-flight 
mass spectrometry (MALDI–ToF–MS), the
α-cyano-4-hydroxycinnamic acid (4-HCCA)
matrix was made saturated in 50% ACN/0.1%
TFA, diluted 1:2, spotted onto plates, and
dried. MALDI–ToF–MS was performed at
the Wallenberg Center North Expression
Proteomics Facility (Uppsala University,
Uppsala, Sweden) using a Bruker Ultraﬂex II
(Bruker Daltonics, Billerica, MA, USA).
The peptide masses were matched with the
theoretical peptide masses of all proteins in 
the National Center for Biotechnology
Information (NCBI) nonredundant database
(http://www.ncbi.nih.gov) using the MASCOT
search engine (http://www.matrixscience.com/;
Perkins et al. 1999). Monoisotopic masses and a
mass tolerance of 0.5 Da was used throughout.
We conﬁrmed further the protein identity of
selected spots (see “Results”) using MALDI–
MS/MS analysis, using Bruker Ultraﬂex II.
Western blot. To simultaneously detect
Gap-43 and the endogenous reference protein
β-tubulin, we used rabbit anti-Gap-43 anti-
body (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) and mouse anti-β-tubulin
antibody (Sigma Chemical Co., St. Louis, MO,
USA), respectively, with the ECL Plex Western
Blotting Detection System (GE Healthcare)
according to the manufacturer’s instructions 
Results 
To explore protein changes associated with
developmental neurotoxicity of PBDE-99, we
used a previously established mouse model 
in which a single oral dose of PBDE-99
(12 mg/kg bw) administered during the neo-
natal period (day 10) induces persistent abnor-
malities in adult spontaneous behavior,
learning, and memory (Eriksson et al. 2001;
Viberg et al. 2004b). The striatum and the
hippocampus from treated and control ani-
mals, respectively, were separately pooled and
subjected to replicated 2D-DIGE analysis
(Figure 1), addressing both biological and tech-
nical variation. To allow for protein identiﬁca-
tion directly from the 2D-DIGE gels, one of
the four replicate gels (gel 4, Figure 1) was a
technical replicate loaded with additional 
unlabeled protein (150 µg) from a control ani-
mal. This increased protein load had no appar-
ent adverse effect on the fluorescent spot
pattern, which was highly similar between gels
regardless of sample type (Figure 2), or on the
quantitative analysis, as indicated by the
reduced variance when including all four repli-
cate gels in the analysis (data not shown). The
average number of spots found in the gels from
the striatum and the hippocampus was 1,893 ±
216 and 1,616 ± 185, respectively, where the
error is the standard error of the mean. Only
the 685 and 651 spots found in all four gels
from the striatum and the hippocampus,
respectively, were used for further analysis. We
determined spots to be differentially expressed
by the following three criteria: a) the log2 fold
change (treated/control) had to be > 95% pre-
diction limit (0.199 for the striatum and 0.242
for the hippocampus; Figure 3) in three of four
gels; b) the average log2 fold change had to be
> 0.263 (corresponding to a 1.2-fold up- or
down-regulation); and c) the difference had 
to be statistically significant (p < 0.01). This 
set of criteria resulted in 40 statistically differ-
entially expressed spots in the striatum
Alm et al.
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Figure 2. 2D-DIGE image of ﬂuorescently labeled proteins from striatum (A) and hippocampus (B) of PD11 mice. Proteins were extracted from the striatum (A) and
hippocampus (B) of mice 24 hr after they received a single oral dose of PBDE-99 (treated) or vehicle (control) on PD10. Proteins were labeled with Cy3 (control),
Cy5 (treated), and Cy2 (mixture of control and treated as internal reference; see “Material and Methods”) and separated on pH 4–7 IPG strips in the ﬁrst dimen-
sion. This procedure was followed by separation on 12.5% SDS–polyacrylamide gels in the second dimension, and the gels were scanned with a Typhoon 9400
ﬂuorescent scanner. The arrows point to the 9 (A) and 10 (B) spots found to be regulated and identiﬁed spots, respectively. The numbers correspond to the num-
bers in Table 1.(Figure 4) and 56 in the hippocampus (not
shown), corresponding to 5.8 and 8.6% of the
spots identified on all four gels, respectively.
We selected spots for protein identification
based on spot intensity (Figure 4) and spot
integrity (Figure 2). Using MALDI–ToF–MS,
we determined the protein identity (Table 1)
for 9 spots from the striatum (Figure 2A) 
and for 10 spots from the hippocampus
(Figure 2B), respectively. These spots were
found to correspond to six (striatum) and nine
(hippocampus) protein identities, respectively,
only one of which (mortalin) was common to
both brain structures (Table 1). Among the
proteins identified from the striatum, two
(represented by 3 spots) were up-regulated 
and four (represented by 6 spots) were down-
regulated by PBDE-99 exposure, whereas all
proteins identiﬁed from the hippocampus were
up-regulated (Table 1). The 3 well-separated
spots (5, 6, and 7; Figure 2A) in the striatum,
identified as stathmin (Table 1), indicate
the existence of three protein variants (all
down-regulated) of similar molecular weight
but different charge. This ﬁnding may imply
alternative posttranslational modiﬁcation or iso-
form expression of this protein, which may also
be the case for the 2 juxtaposed but distinctively
separate spots (8 and 9; Figure 2A) in the stria-
tum identiﬁed as Gap-43 (neuromodulin), and
for spots 5 and 6 (Figure 2B) in the hippocam-
pus, identiﬁed as γ-enolase (Table 1), respec-
tively. The identity of spot 8 in the striatum,
1 of the 2 juxtaposed spots (8 and 9; Figure 2A)
identified as Gap-43 (Table 1) in a separate
preparative gel (not shown), was further
confirmed by MALDI–MS/MS (Figure 5).
The increased level of Gap-43 in the striatum
but not in the hippocampus after PBDE-99
treatment was confirmed by Western blot
(Figure 6).
Discussion
Neurotoxicity of PBDEs in the neonatal
mouse has been shown ultimately to target the
developing cholinergic and catecholaminergic
systems (Mariussen and Fonnum 2003;
Meerts et al. 2004; Viberg et al. 2002, 2003a,
2004b). However, the cellular events from the
period of BGS to permanent impairment of
adult spontaneous behavior and memory
functions (Eriksson et al. 2001) are not fully
understood. We used 2D-DIGE, a powerful
proteomics approach for identifying quantita-
tive protein differences between two samples
(Tonge et al. 2001), to show that a single dose
of PBDE-99 in neonatal mice induces rela-
tively rapid (within 24 hr of exposure) changes
in the levels of several proteins in two critical
brain regions of the developing cholinergic
and monoaminergic systems, the striatum and
the hippocampus (Table 1). It has been shown
earlier that neonatal PBDE-99 exposure in
this mouse model is associated with a 1.2-fold
decrease in the density of cholinergic nicotinic
receptors in the hippocampus at an adult age
(Viberg et al. 2004b). In the present study, we
identify various other proteins that change
> 1.2-fold with statistical significance (p <
0.01) in these brain regions neonatally. Even if
2D gel electrophoresis may be unrivaled
among protein separation techniques in terms
of resolution, its major limitation is lack of
sensitivity (Yarmush and Jayaraman 2002).
Hence, the fluorescent spots discernible in
Figure 2 represent only a few of the most
abundantly expressed proteins in each brain
structure. In other words, the proteins for
which we detect significantly altered levels
shortly after exposure to PBDE-99 (Table 1)
are likely to be major cellular components.
Moreover, the highly similar ﬂuorescent spot
patterns in gels separating proteins from the
striatum (Figure 2A) and the hippocampus
(Figure 2B) indicate that both of these brain
structures may express essentially the same
major proteins on postnatal day (PD) 11,
Neonatal PBDE-99 neurotoxicity
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Table 1. Protein identities.
No. of peptides Fold change
Spot no. Protein identitya Accession no.b Scorec matched  up (+)/down (–)
Striatum
1 Albumin-fragment Q8CG74 89 32 –1.41
2 Albumin 1 Q8C7H3 308 29 –1.24
3 Mortalin GRP75_MOUSE 213 24 +1.96
4 Methylglyoxalase LGUL_MOUSE 74 7 –1.33
5 Stathmin STN1_MOUSE 103 10 –1.30
6 Stathmin STN1_MOUSE 137 13 –1.21
7 Stathmin STN1_MOUSE 106 11 –1.26
8 Neuromodulin (Gap-43) P06837 92 8 +1.31
9 Neuromodulin (Gap-43) P06837 85 8 +1.25
Hippocampus
1 Mortalin GRP75_MOUSE 125 15 +1.52
2 CCT (TCP-1) TCPB_MOUSE 242 23 +1.21
3 Atp5b ATPB_MOUSE 219 22 +1.23
4 Macropain Q8BKU2 125 11 +1.21
5 Gamma enolase ENOG_MOUSE 229 20 +1.22
6 Gamma enolase ENOG_MOUSE 256 22 +1.24
7 Alpha enolase ENOA_MOUSE 216 20 +1.27
8 Laminin receptor 1 P14206 148 12 +1.27
9 Idh3a Q9D6R2 101 10 +1.58
10 Synuclein, alpha Q9CXF8 114 9 +1.41
aThe identities of 11 spots from striatum and 10 spots from hippocampus, determined by MALDI–ToF–MS peptide mass ﬁnger-
printing. bAccession numbers are from the NCBI nonredundant database (http://www.ncbi.nih.org).cThe searches were made
using the MASCOT search engine (http://www.matrixscience.com). The peptide masses were matched with the theoretical
peptide masses of all proteins in the NCBI nonredundant database. Protein scores > 61 are signiﬁcant (p<0.05).
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Figure 3. Box plots of the spot ratios from the four
gels from the (S) striatum and the (H) hippocampus.
The box limits are the first and third quartile,
closely representing 50% of the data. The whiskers
extend to the most extreme data point, which is no
more than 1.5 times the length of the box away
from the box. The overall average and SD of the
log2 95% ratios averages 0.141 ± 0.016 for the stria-
tum and 0.165 ± 0.022 for the hippocampus, corre-
sponding to log2 95% prediction limits of 0.199 and
0.242, respectively. S1–S4, gels 1–4 (see Figure 1)
for striatum; H1–H4, gels 1–4 for hippocampus.
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Figure 4. Measurement of relative expression ver-
sus average log intensity (MA) plot showing the
result of the statistical analysis of the striatum pro-
teins. The log2 values of spot intensity on the y-axis
are plotted against log2 values of fold change on
the x-axis. The intensity was calculated as the log2
of the raw intensity of the average of Cy3 and Cy5
across all four gels. The spots correspond to the
striatum proteins identified on all four DIGE gels.
The spots marked in blue represent the differently
regulated proteins, whereas the squared blue
spots represent the nine proteins picked and iden-
tiﬁed from the striatum gel 4.thereby showing their functional importance
under normal conditions of BGS. Any altered
levels of such proteins, being either a cause or
a consequence of cellular events initiated by
PBDE-99 action, would be expected to have
effects on or reﬂect processes related to neural
development and brain maturation.
Neurite sprouting and outgrowth are
among the critical processes occurring during
the BGS period. We found PBDE-99 to
induce signiﬁcantly increased levels of neuro-
modulin (Gap-43), and decreased levels of
stathmin in the striatum (Table 1) but not in
the hippocampus. The expression of neuro-
modulin and stathmin closely correlates with
neurite outgrowth (Grenningloh et al. 2004;
Skene 1989). The expression of neuromodulin
is nerve cell–speciﬁc and developmentally reg-
ulated (Oestreicher et al. 1997). It has become
evident that neuromodulin plays key roles
in guiding the growth of axons and in modu-
lating the formation of new connections
(Benowitz and Routtenberg 1997), as in re-
induction of axonal growth for regeneration
after damage (Skene 1989). Similar changes
(i.e., up-regulation of neuromodulin and
down-regulation of stathmin) have been
observed in neurodegenerative disorders such
as Alzheimer disease (Cheon et al. 2001;
Rekart et al. 2004), most likely reflecting
compensatory sprouting.
Interestingly, both neuromodulin and
stathmin are protein kinase C (PKC) substrates
(Duraj et al. 1995; Iannazzo 2001). The role of
PKC signaling in neuronal development and
function as well as in learning and memory
processes has been intensely studied (Birnbaum
et al. 2004; Rekart et al. 2005), and PKC iso-
forms are among the few proteins known to be
affected by PBDE-99 (Kodavanti and Ward
2005; Madia et al. 2004). For example,
PBDE-99 has been reported to induce activa-
tion of PKC isoforms α, ε, and ζ in astro-
cytoma cells in vitro (Madia et al. 2004). In
primary cultures of rat cerebellar granule neu-
rons, PBDE-71 and PCBs stimulate the release
of arachidonic acid (Kodavanti and Derr-Yellin
2002), a cis-unsaturated free fatty acid that
activates PKC-ε (Yaguchi et al. 2005), through
a mechanism dependent on phospholipase A2
(PLA2) activity (Nishizuka 1995).
In the hippocampus of animals exposed to
PBDE-99, we found increased levels of three
metabolic proteins previously reported to be
components of PKC-ε signaling complexes
(Edmondson et al. 2002): α-enolase; ATP
synthase, H+ transporting mitochondrial F1
complex, β subunit (Atp5b); and isocitrate
dehydrogenase 3 (NAD+) α (Idh3a) (Table 1).
We also detected an increase of γ-enolase in
the hippocampus (Table 1) and an increase,
although not statistically significant (data
not shown), of α-enolase in the striatum.
Heterodimers of α- and γ-enolases have been
observed in rat brain synaptic terminals (Ueta
et al. 2004), but any co-regulation of these
proteins in the mouse hippocampus in response
to PBDE-99 has yet to be determined.
Several lines of evidence thus point toward a
possible role for PKC signaling as a proxi-mate
target for the neurotoxicity of PBDE-99. PKC
activity has also been reported to be affected by
other environmentally relevant xenobiotics
such as dioxins (Kim and Yang 2005), PCBs
(Tilson and Kodavanti 1998), and tetrabromo-
bisphenol A (Reistad et al. 2005).
It is well established that the brain is vul-
nerable to exogenous insults during the BGS
period (Eriksson 1997; Ikonomidou et al.
2000; Olney 2004). Also, an accentuation 
of the naturally occurring apoptosis, often
termed “physiological cell death” (PCD), has
been observed in the hippocampus of mice on
PD11 following exposure on PD10 to pharma-
cologic compounds that affect the N-methyl-
D-aspartate (NMDA) and γ-aminobutyric acid
(GABA) systems (Fredriksson et al. 2004).
Eriksson’s group has shown previously that
neonatal exposure (PD10) to PBDE-99 leads to
impaired working memory in hippocampus-
related behavioral tests in adulthood (Eriksson
et al. 2001). Interestingly, behavioral effects
after exposure to NMDA antagonists mimic
the effects of PBDE-99 exposure (Fredriksson
et al. 2004). However, to our knowledge, no
studies have shown an accentuated apoptosis
after PBDE-99 treatment. Nonetheless, a
recent in vitro study showed that PBDE-99
causes apoptotic cell death in an astrocytoma
cell line (Madia et al. 2004). Future studies will
reveal if PBDE-99 potentiates apoptosis
through this pathway in the developing brain
in vivo.
In conclusion, we present data suggesting
that in neonatal mice, early exposure to
PBDE-99 may induce cellular stress and that
neurodegeneration in combination with aber-
rant neuroplasticity during this critical stage of
brain development may contribute to the late
effects in behavior observed in adult mice. It is
interesting to note the differences in response
to PBDE-99 between the hippocampus and
the striatum. Although the general pattern of
highly expressed proteins in the two brain parts
was strikingly similar, the responses to
PBDE-99 were apparently discrete, reﬂecting
the underlying heterogeneity between different
brain parts and cell populations. Also, a pri-
mary effect in one cell region with axonal pro-
jections to other regions would most likely
affect the protein expression in the latter
regions. By studying molecular effects at the
protein level soon after exposure, we have iden-
tiﬁed proteins that can be evaluated as poten-
tial biomarkers that reflect the immediate
consequences of early exposure to PBDE-99,
and that may provide insights into the
processes underlying persistent neurotoxicity.
Alm et al.
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Figure 5. MS/MS identiﬁcation of Gap-43 (neuromodulin). MS/MS spectrum for spot 10 in Figure 2A. The
parent ions m/z 1986.91 and 1217.56 were used for MS/MS identiﬁcation.
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Figure 6. Western blot validation of Gap-43 expres-
sion. Gap-43 and the endogenous reference pro-
tein β-tublin were simultaneously detected in
control (–) and PBDE-99–exposed (+) striatum (S)
and hippocampus (H) samples after SDS–PAGE
and electroblotting to nitrocellulose. Neonatal PBDE-99 neurotoxicity
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